PPD Named Clinical Research Company of the Year for Second Consecutive Year
19 Ottobre 2021 - 3:00PM
Business Wire
PPD, Inc. (Nasdaq: PPD) was named “Clinical Research Company of
the Year” at the 2021 PharmaTimes Clinical Researcher of the Year
International competition in London.
In addition to PPD winning the highest honor, individual PPD
clinical researchers won gold and silver in both the Clinical
Research Team and Start Up-Singles categories, as well as silver
and bronze awards in the Aspiring Clinical Research Associate (CRA)
category and bronze in the In-House CRA category.
“This is the second year in a row that PPD has won this award,
and we are thrilled that our clinical researchers continue to be
recognized by PharmaTimes for their talent, work ethic and
commitment to this industry year after year,” said Amber Lee,
senior vice president of clinical operations for PPD. “Our clinical
research professionals are key to our customers’ success, as they
help advance safe and effective treatment options through clinical
trials.”
The recognition demonstrates the high caliber of PPD’s clinical
research professionals and the effectiveness of PPD’s award-winning
training and development programs, such as the company’s Clinical
Foundations Program and its CRA Academy. These programs help to
prepare and equip research professionals to deliver strong
performance, quality and value to PPD customers.
The Clinical Researcher of the Year Awards are the culmination
of a rigorous series of assessments, including a three-stage
competition concluding in presentations before a panel of
experienced industry judges. The event was created to provide
clinical research professionals an opportunity to benchmark their
professional skills against their peers in a program of
competency-based exercises developed through cross-industry
collaboration.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With more than 30,000 professionals
worldwide, PPD has conducted clinical trials in more than 100
countries to help customers deliver life-changing therapies to
improve health. We apply innovative technologies, therapeutic
expertise and a firm commitment to quality to bend the cost and
time curve of drug development and optimize value. For more
information, visit www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the proposed merger of
PPD by Thermo Fisher Scientific Inc.; and other factors disclosed
under the “Risk Factors” section in our periodic reports filed with
the Securities and Exchange Commission (SEC), including our latest
Annual Report on Form 10-K and Quarterly Report on form 10-Q, which
are available on our website at https://investors.ppd.com or the
SEC’s website at www.sec.gov. We assume no obligation and disclaim
any duty to revise or update any forward-looking statements, or
make any new forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211019005734/en/
Media: Nadine Maeser +1 919 456 4425 media@ppd.com
Investors: Tracy Krumme +1 910 558 4186 investors@ppd.com
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Ott 2023 a Ott 2024